Sintilimab

Generic Name: Sintilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2072873-06-2

Unique Ingredient Identifier: 8FU7FQ8UPK

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer

Phase 2

Recruiting

Conditions: Esophageal Cancer

First Posted Date: 2024-05-08

Last Posted Date: 2024-05-08

Lead Sponsor: Sichuan University

Target Recruit Count: 68

Registration Number: NCT06403878

Locations: 🇨🇳
West-China Hospital, Chengdu, China

Sintilimab Combined With Fruquintinib/Regorafenib ± Radiotherapy for Third-line Treatment of Advanced Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Radiotherapy
Targeted Therapy
Colorectal Cancer
Immunotherapy

Interventions: Drug: Sintilimab

First Posted Date: 2024-04-10

Last Posted Date: 2024-04-10

Lead Sponsor: Shandong Cancer Hospital and Institute

Target Recruit Count: 141

Registration Number: NCT06356584

Locations: 🇨🇳
Jinbo Yue, Jinan, Shandong, China

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

Not Applicable

Recruiting

Conditions: Chronic Hepatitis B

Interventions: Drug: Sintilimab
Drug: NAs
Drug: Peg-IFNα-2b

First Posted Date: 2024-04-10

Last Posted Date: 2024-06-12

Lead Sponsor: Beijing 302 Hospital

Target Recruit Count: 45

Registration Number: NCT06357806

Locations: 🇨🇳
the Fifth Medical Center, Chinese PLA General Hospital, Beijing, Beijing, China

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Early Phase 1

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: Sintilimab
Drug: Inulin

First Posted Date: 2024-04-04

Last Posted Date: 2024-04-04

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 30

Registration Number: NCT06347198

Locations: 🇨🇳
Min Jin, Wuhan, Hubei, China

Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM

Phase 2

Recruiting

Conditions: Gastric Cancer
Gastric Cancer Metastatic to Regional Lymph Nodes

Interventions: Drug: Sintilimab
Radiation: Extraperitoneal radiation therapy
Drug: Oxaliplatin
Drug: S-1

First Posted Date: 2024-04-02

Last Posted Date: 2024-04-02

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 40

Registration Number: NCT06341595

Locations: 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Recruiting

Conditions: Lenvatinib
Hepatocellular Carcinoma
PD-1 Inhibitor
Hepatic Arterial Infusion Chemotherapy

Interventions: Procedure: Hepatic arterial infusion chemotherapy
Drug: Lenvatinib
Drug: Tislelizumab
Drug: Toripalimab
Drug: Sintilimab
Drug: Camrelizumab

First Posted Date: 2024-03-27

Last Posted Date: 2024-10-15

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 300

Registration Number: NCT06333561

Locations: 🇨🇳
Chinese PLA General hospital, Beijing, Beijing, China

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Recruiting

Conditions: Bevacizumab
Advanced Hepatocellular Carcinoma
Anti-PD1/PDL1 Antibody

First Posted Date: 2024-03-21

Last Posted Date: 2024-03-21

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 240

Registration Number: NCT06323382

Locations: 🇨🇳
Chinese PLA hospital, Beijing, Beijing, China

Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Radiation: Stereotactic body radiotherapy
Drug: Sintilimab

First Posted Date: 2024-03-15

Last Posted Date: 2024-11-18

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 140

Registration Number: NCT06313190

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Phase 2

Not yet recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Eribulin
Drug: Sintilimab

First Posted Date: 2024-03-13

Last Posted Date: 2024-03-13

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 81

Registration Number: NCT06308939

Locations: 🇨🇳
zhejiangCH, Hangzhou, Zhejiang, China

Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Procedure: TOMOX-HAIC
Drug: Sintilimab
Drug: Bevacizumab

First Posted Date: 2024-02-29

Last Posted Date: 2024-02-29

Lead Sponsor: Fudan University

Target Recruit Count: 65

Registration Number: NCT06285019

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy